

UNIVERSITI TEKNOLOGI MARA

**ORAL ABSORPTION STUDY OF LEVODOPA-
LOADED CHITOSAN MICROPARTICLES**

MOHAMAD ZHAFRAN BIN KAMARUZAMAN

BACHELOR OF PHARMACY

**Dissertation submitted in partial fulfillment of the requirements for
the Bachelor of Pharmacy (Hons.)**

Faculty of Pharmacy

2014

ABSTRACT

Levodopa is the most common drug that has been used to treat Parkinson Disease. This study was conducted to increase the bioavailability of levodopa after size reduction and to study the pharmacokinetic profiles of levodopa loaded chitosan microparticles after oral administration. Levodopa-loaded chitosan microparticles has been formulated by using ionic gelation method. The characterization of microparticle was carried out by using Malvern Particle Size Analyzer to evaluate the mean particle size and uniformity of levodopa-loaded chitosan microparticle which was 39.9 μm . By using Scanning Electron Microscopy (SEM), the morphology of the levodopa loaded chitosan microparticle showed levodopa was encapsulated in the chitosan-sodium TPP polymer. The value of drug entrapment efficiency for the levodopa loaded chitosan was 75.06%. Fourier Transform Infrared (FTIR) showed that there was interaction and extension of hydrogen bonding between sodium TPP. The characterization by using X-Ray Diffraction showed the amorphous state of levodopa loaded chitosan after blended with chitosan. By pharmacokinetic study, it showed AUC value was $5664.19 \pm 132 \mu\text{g/ml.min}$ as compared to the control (3436.17 ± 385.52). The concentration of levodopa microparticles was significantly increased ($p < 0.05$) as compared to unprocessed levodopa.

ACKNOWLEDGEMENTS

All the praises and thanks be to Allah. With His all blessings, I have enough strength to complete my research. Firstly, I would like to express my gratitude to my supervisor, Dr Khuriah Abdul Hamid for her continuous support and encouragement. All of guidance and knowledge that she gave, helping me so much in completing my study.

My completion of this project could not have been accomplished without the support from the postgraduate students namely, Mohd Zulhelmy Ahmad, Mohd Fattah, Mohd Hafiz. I would appreciate their contribution in completing my research. My appreciation also goes to laboratory staffs that guiding me in using equipments in the laboratory throughout the research course.

Special thanks goes to my lab-mate; Muzzamil bin Mazlan, Arif Aizat Bin Affendi, Mastria binti Mohamed and Mastura binti Omar for their help and input to complete this study. Last but not least, a big appreciation goes to my family especially my parents for always being supportive during my hard times. May Allah bless you all always.

TABLE OF CONTENT

1. CHAPTER 1 : INTRODUCTION	1
1.1 Background of Research	1
1.2 Problem Statement	4
1.3 Objectives	4
1.4 Significance of Study	5
2. CHAPTER 2: LITERATURE REVIEW	6
2.1 Chitosan	6
2.1.1 Overview of Chitosan	6
2.1.2 Properties of Chitosan in Pharmaceutical Industry	7
2.2 Parkinson's Disease	8
2.2.1 Introduction of Parkinson's Disease	8
2.2.2 Molecular Mechanism of Dopamine	9
2.2.3 Pathophysiology of Parkinson's Disease	10
2.3 Levodopa	11
2.3.1 Overview of Levodopa	11
2.3.2 Mechanism of Levodopa in Treating Parkinson's Disease	12
2.3.3 Levodopa-loaded Chitosan Microparticles	13
2.4 Oral Drug Delivery	14
2.4.1 Overview of Oral Drug Delivery	14
2.5 Barrier to Membrane Absorption	16
2.5.1 Efflux by Permeability Glycoprotein	16

CHAPTER 1

INTRODUCTION

1.1 BACKGROUND OF RESEARCH

Nowadays, polymer- micro and nanoparticles have been used widely in drug delivery system (Valente et al., 2012). Polymer nanoparticles as a carrier for drug delivery that biodegradable and biocompatible with the human body are suitable to deliver the drug to the target (Tahara et al., 2009). This type of carrier solves many problems with drugs such as insufficient dose, low solubility/dissolution, poor stability of the therapeutics and also uncertain potency. Nanoparticles are quite interesting candidates for drug delivery because of their benefits such as the ability to provide a large surface area and promote mass transfer of small molecules with precise kinetics (Valente et al., 2012). In the body, this drug delivery system can provide accurate dose of drug, with the right time, to the right target location, increase efficacy and compliance with minimize side effect of drug.

Basically, oral routes become a most frequent and convenient one to deliver the drug due to its high absorption in the small intestine. But, there are some limitations because the delivery of the drug moves through the digestive tract. Normally, absorption begins in the mouth and stomach but most drug usually absorbed from the small intestine before the drug travel to the liver. Differential drug